ArticleFrontiers in medicine2026
675-nm diode laser as an adjuvant treatment for telogen effluvium: case series.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telogen effluvium (TE) is a diffuse, non-scarring alopecia that can have a significant impact on quality of life. Although often self-limited, many patients seek therapies that speed recovery. Photobiomodulatory benefits of the 675-nm diode laser are also well established in treating other hair disorders, but there is limited evidence in TE. Methods: We performed a retrospective case series of 13 patients diagnosed with TE at a Dermatologic Laser Center in Mexico. The patients received adjuvant treatment with 675-nm diode laser therapy. Results: Of the 13 patients, 69% had chronic TE. Among those with a positive baseline pull test, 72% became negative at follow-up. Pruritus improved in 83% of symptomatic patients, and trichodynia resolved in 75%. No adverse events occurred. Conclusion: 675-nm diode laser seems to be a safe, well-tolerated, and potentially effective adjuvant therapy for TE. Controlled studies are needed to confirm efficacy and establish standardized protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.